A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

Forbes Medi-Tech Inc.

About Forbes Medi- Tech Inc

Forbes Medi-Tech Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of innovative prescription pharmaceutical and nutraceutical products derived from by-products of the forestry industry and other natural sources for the prevention and treatment of cardiovascular and related diseases. The Company's scientific platform is based on core sterol technology. Forbes has developed cholesterol-lowering agents for use in pharmaceutical compounds, functional foods and dietary supplements.


Product Pipeline



FM-VP4, a novel analogue of phytostanols, has demonstrated dramatic cholesterol-lowering and anti-atherosclerotic properties in pre-clinical trials. FM-VP4 is currently being evaluated in a Phase II clinical trial at the Academic Medical Center, University of Amsterdam, one of the world's leading centers for the research and management of dyslipidemia.

The FM-VPx Library of Compounds represents a group of synthetic entities with therapeutic potential targeting the cardiovascular market. These compounds may have additional benefits including: triglyceride-lowering, increasing HDL (good cholesterol), anti-obesity, anti-diabetic, and anti-inflammatory.


More on Forbes Medi-Tech


Home Page

Key Statistics for Forbes Medi-Tech

Basic Chart for Forbes Medi-Tech


Biotech100 Index
What are the Requirements to be listed in the Biotech100 Index?
See the Biotech100 List

Sponsored Links

Clinical Trials
What is a Clinical Trial?
Phase I ,-- Phase II, -- PhaseIII
What is Randomized Control?
 What is a Double Blind Experiment?
What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
Small Cap Stocks
Stocks and Bonds
Biotech100 Index

Careers and Employment
Biotechnology and Pharmaceutical
What are the Fastest Growing Careers?




Copyright 2005 BIOTECH100.COM. All rights reserved.